Ignite Creation Date:
2025-12-24 @ 1:31 PM
Ignite Modification Date:
2026-04-22 @ 11:34 AM
Study NCT ID:
NCT01473095
Status:
COMPLETED
Last Update Posted:
2017-10-23
First Post:
2011-11-10
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma
Sponsor:
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
ARQ 092-101
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None